(E)-3-(2-bromophenyl)-1-(3-chlorophenyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(2-bromophenyl)-1-(3-chlorophenyl)prop-2-en-1-one
• 化学式: C₁₅H₁₀BrClO
• 分子量: 321.59
• InChiKey: SYYXAYHNDXQXFO-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'IMMUNOSUPPRESSION DONT LA MÉDIATION EST ASSURÉE PAR LA MÉTABOLISATION DU TRYPTOPHANE
  申请人：NEWLINK GENETICS CORP

  公开号：WO2014159248A1

  公开（公告）日：2014-10-02

  Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供的是IDO和TDO的抑制剂及其药物组合物，用于调节吲哌啶2,3-二氧化酶和色氨酸2,3-二氧化酶的活性；治疗免疫抑制；治疗受益于色氨酸降解抑制的医疗状况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染病相关的免疫抑制。
• Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization
  申请人：NEWLINK GENETICS CORPORATION

  公开号：US20160060266A1

  公开（公告）日：2016-03-03

  Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.

  目前提供的是IDO和TDO的抑制剂及其制药组合物，用于调节吲哚酮2,3-二氧化酶和色氨酸2,3-二氧化酶的活性；治疗免疫抑制；治疗从色氨酸降解抑制中受益的医疗状况；增强包括给予抗癌药剂在内的抗癌治疗的效果；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染病相关的免疫抑制。
• TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION
  申请人：Newlink Genetics Corporation

  公开号：EP3366678A1

  公开（公告）日：2018-08-29

  Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associates with cancer; and treating immunosupression associated with an infectious disease.

  目前提供的是IDO和TDO的抑制剂及其药物组合物，可用于调节吲哚胺2,3-二氧合酶和色氨酸2,3-二氧合酶的活性；治疗免疫抑制；治疗从抑制色氨酸降解中获益的病症；提高通过施用抗癌剂进行抗癌治疗的效果；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制。
• TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION.
  申请人：Newlink Genetics Corporation

  公开号：EP2976332B1

  公开（公告）日：2018-01-31
• US9617272B2
  申请人：——

  公开号：US9617272B2

  公开（公告）日：2017-04-11